Aiolos Bio Launches with $245M Series A
San Francisco & London, October 24, 2023 (Business Wire) -- Aiolos Bio, Inc. has launched as a clinical-stage biopharmaceutical company that aims to address the unmet respiratory and inflammatory treatment needs of patients. The company has raised $245 million in a Series A investment round, co-led by Atlas Venture, Bain Capital Life Sciences, Forbion, and Sofinnova Investments, with additional investment from RA Capital Management. Aiolos Bio’s lead drug candidate, AIO-001, will be advanced into a Phase 2 clinical trial for moderate-to-severe asthma patients, and the company is actively exploring additional development opportunities.
Read full article here.